KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.

Germán Áñez, Lisa M Dunkle, Cynthia L Gay, Karen L Kotloff, Jeffrey M Adelglass, Brandon Essink, James D Campbell, Shane Cloney-Clark, Mingzhu Zhu, Joyce S Plested, Pavitra Roychoudhury, Alexander L Greninger, Nita Patel, Alice McGarry, Wayne Woo, Iksung Cho, Gregory M Glenn, Filip Dubovsky, 2019nCoV-301–Pediatric Expansion Study Group

JAMA Netw Open 6(4) e239135

PMID37099299
PMCIDPMC10536880
DOI10.1001/jamanetworkopen.2023.9135
发表日期2023-04-26
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

IMPORTANCE: Greater than 20% of cases and 0.4% of deaths from COVID-19 occur in children. Following demonstration of the safety and efficacy of the adjuvanted, recombinant spike protein vaccine NVX-CoV2373 in adults, the PREVENT-19 trial immediately expanded to adolescents. OBJECTIVE: To evaluate the safety, immunogenicity, and efficacy of NVX-CoV2373 in adolescents. DESIGN, SETTING, AND PARTICIPANTS: The NVX-CoV2373 vaccine was evaluated in adolescents aged 12 to 17 years in an expansion of PREVENT-19, a phase 3, randomized, observer-blinded, placebo-controlled multicenter clinical trial in the US. Participants were enrolled from April 26 to June 5, 2021, and the study is ongoing. A blinded crossover was implemented after 2 months of safety follow-up to offer active vaccine to all participants. Key exclusion criteria included known previous laboratory-confirmed SARS-CoV-2 infection or known immunosuppression. Of 2304 participants assessed for eligibility, 57 were excluded and 2247 were randomized. INTERVENTIONS: Participants were randomized 2:1 to 2 intramuscular injections of NVX-CoV2373 or placebo, 21 days apart. MAIN OUTCOMES AND MEASURES: Serologic noninferiority of neutralizing antibody responses compared with those in young adults (aged 18-25 years) in PREVENT-19, protective efficacy against laboratory-confirmed COVID-19, and assessment of reactogenicity and safety. RESULTS: Among 2232 participants (1487 NVX-CoV2373 and 745 placebo recipients), the mean (SD) age was 13.8 (1.4) years, 1172 (52.5%) were male, 1660 (74.4%) were White individuals, and 359 (16.1%) had had a previous SARS-CoV-2 infection at baseline. After vaccination, the ratio of neutralizing antibody geometric mean titers in adolescents compared with those in young adults was 1.5 (95% CI, 1.3-1.7). Twenty mild COVID-19 cases occurred after a median of 64 (IQR, 57-69) days of follow-up, including 6 among NVX-CoV2373 recipients (incidence, 2.90 [95% CI, 1.31-6.46] cases per 100 person-years) and 14 among placebo recipients (incidence, 14.20 [95% CI, 8.42-23.93] cases per 100 person-years), yielding a vaccine efficacy of 79.5% (95% CI, 46.8%-92.1%). Vaccine efficacy for the Delta variant (the only viral variant identified by sequencing [n = 11]) was 82.0% (95% CI, 32.4%-95.2%). Reactogenicity was largely mild to moderate and transient, with a trend toward greater frequency after the second dose of NVX-CoV2373. Serious adverse events were rare and balanced between treatments. No adverse events led to study discontinuation. CONCLUSIONS AND RELEVANCE: The findings of this randomized clinical trial indicate that NVX-CoV2373 is safe, immunogenic, and efficacious in preventing COVID-19, including the predominant Delta variant, in adolescents. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04611802.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。